Therapeutic Experience of Vincristine/cyclophosphamide/melphalan or Mitoxantrone/prednisone Combination Therapy Plus Thalidomide As First‐line Induction Therapy for Newly Diagnosed Multiple Myeloma in a Single Institution of China

Xiaoning Wang,Pengcheng He,Caili Guo,Chunhong Sun,Mei Zhang

DOI: https://doi.org/10.1111/ajco.12609

2016-01-01

Asia-Pacific Journal of Clinical Oncology

Abstract:INTRODUCTION:To investigate the safety and efficacy of the combination regimen vincristine, cyclophosphamide, melphalan or mitoxantrone and prednisone (VCMP) plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma (MM).METHODS:Three hundred and ninety-six symptomatic, newly diagnosed MM patients were treated with VCMP plus thalidomide in our hospital for the past 11 years, and clinical data of these patients were retrospectively analyzed.RESULTS:Of the 396 patients enrolled, the total response rate was 77.3%. Forty-three patients relapsed after sCR and CR. Mean cycles to first response were six cycles (range 1-16 cycles). A total of 53% of patients achieved at least a PR within the first cycle of therapy. The actuarial 1-year, 3-year and 5-year overall survival of all patients were 89.4%, 29.5% and 10.6%, respectively. The probabilities of 1-year, 3-year and 5-year progression-free survival of all patients were 84.0%, 23.1% and 8.4%, respectively. The major adverse events were gastrointestinal symptoms, electrolytes and glucose metabolism disorders, hypertension, infection, peripheral nerve disease and hematological adverse events, which were mostly below grade 3 and could be alleviated by symptomatic treatment.CONCLUSION:We concluded that VCMP plus thalidomide is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed MM including elderly patients and patients with renal failure.